Literature DB >> 890695

Antitumor activity of 4-demethoxydaunorubicin administered orally.

A Di Marco, A M Casazza, G Pratesi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 890695

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  29 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  Phase II trial of idarubicin in patients with advanced lymphoma.

Authors:  H Gillies; R Liang; H Rogers; P Harper; L Parapia; G Cox; S Johnson
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 3.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 4.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

5.  Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study.

Authors:  S Eridani; N G Slater; A K Singh; T C Pearson
Journal:  Blut       Date:  1985-06

Review 6.  Clinical pharmacokinetics of idarubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.

Authors:  F Formelli; A M Casazza; A Di Marco; A Mariani; C Pollini
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

Authors:  H C Gillies; D Herriott; R Liang; K Ohashi; H J Rogers; P G Harper
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

9.  Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin.

Authors:  D B Smith; J M Margison; S B Lucas; P M Wilkinson; A Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Intravesical idarubicin--a phase-I study.

Authors:  W Schultze-Seemann; K Mross; K Burk; H Sommerkamp
Journal:  Urol Res       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.